"Evaluating system accuracy of blood glucose monitoring systems for point of care
testing"
Embargo lifts: Saturday, June 22, 10 am CST
Presenter: G. Freckmann, Institut fuer Diabetes-Technologie Forschungs- und
Entwicklungsgesellschaft mbH an der Universitat Ulm, Germany
Location: Poster Hall (also available as an ePoster on the ADA website after 10
am, June 22)
Sanofi will host a conference call for the financial community during the upcoming ADA 73rd Scientific Sessions. The call will include results from the ongoing EDITION Phase III program for the company's investigational new insulin U300 as well as a status update on the fixed-ratio combination of insulin glargine and lixisenatide.
The conference call will take place on Monday June 24, 2013, at 7 am CST (2 pm CET). Dial-in numbers and the audio webcast link will be accessible via http://www.sanofi.com
About Diabetes
Diabetes is a chronic disease that occurs as type 1 diabetes, which is an autoimmune disease characterized by the lack of insulin (the hormone that regulates blood glucose concentrations) production by the pancreas, and type 2, a metabolic disorder in which there are two main biological defects: a deficient production of insulin and reduced ability of the body to respond to the insulin being produced. Type 1 and type 2 diabetes are characterized by an increase in blood glucose concentrations (hyperglycemia). Over time, uncontrolled hyperglycemia leads to the macrovascular and microvascular complications of diabetes. Macrovascular complications, which affect the large blood vessels, include heart attack, stroke and peripheral vascular disease. Microvascular complications affect the small blood vessels of the eyes (retinopathy), kidney (nephropathy) and nerves (neuropathy). The global incidence of diabetes is growing at an alarming rate, with more than 371 million people worldwide living with the condition today.[2]
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services and devices, including blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.
About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris and in New York .
Footnote
Lixisenatide, | a | glucagon-like | peptide-1 | receptor | agonist | (GLP-1 | RA), | was | in-licensed | from | Zealand | Pharma | A/S | , | | target="_blank" | rel="nofollow" | href="http://www.zealandpharma.com">http://www.zealandpharma.com, | and | is | approved | in | Europe, | Mexico | and | Australia | for | the | treatment | of | patients | with | type | 2 | diabetes | mellitus. | Lyxumia | is | the | proprietary | name | approved | by | the | EMA, | Australia | and | Mexico, | and | submitted | to | other | health | authorities | for | the | GLP-1 | RA | lixisenatide. | The | proprietary | name | for | lixisenatide | in | the | United | States | is | under | consideration |
References
1. Gerstein H (ORIGIN Trail Investigators) et al. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine 2012; 367: 319-328.
2. International Diabetes Federation. IDF Diabetes Atlas, 5th edition: 2012 update. Brussels, Belgium, 2011. http://www.idf.org/diabetesatlas (Accessed: June, 2013)
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
CONTACT: Contacts: Corporate Media Relations, Marisol Péron, Tel:+33-1-53-77-45-02, Mobile: +33-6-08-18-94-78, E-mail:marisol.peron@sanofi.com ; Investor Relations: Sébastien Martel, Tel:+33-1-53-77-45-45, E-mail: ir@sanofi.com; Global Diabetes DivisionCommunications: Phil McNamara, Tel: + 1-908-981-5497Mobile: +1-908-210-4047, E-mail: philip.mcnamara@sanofi.com